Fluid Resuscitation - PowerPoint PPT Presentation

1 / 76
About This Presentation
Title:

Fluid Resuscitation

Description:

Heparin bolus and infusion started ... Bolus SK to 35 yr woman 4 days post-partum. Successfully resuscitated and d/c 2/52 later ... – PowerPoint PPT presentation

Number of Views:388
Avg rating:3.0/5.0
Slides: 77
Provided by: caep
Category:

less

Transcript and Presenter's Notes

Title: Fluid Resuscitation


1
Dr. Dan Howes Queens University
Controversies and Progress in Resuscitation 2009
Dr. Jason Lord University of Calgary
2
Declaration of potential conflict of interest
  • Dr. Lord has received honoraria from
  • Eli Lilly
  • Bristol Myers Squibb
  • Dr. Howes has received research funding from Life
    Recovery Systems, but so far no one is willing to
    pay for his opinion.

3
Topics
  • Advances in transfusion resuscitation
  • Controversies with Massive Submassive PE
  • Cognitive Psychology gets practical

4
Advances in Transfusion Medicine
5
Case 1
  • 54 YO cyclist strikes the side of a car at a high
    rate of speed
  • Injuries include multiple orthopedic injuries,
    hemothorax, splenic and liver lacerations, pelvic
    fracture.
  • Conscious, responding appropriately gtgt
  • decreasing level of consciousness

6
  • BP 85/30
  • HR 135
  • RR 16
  • IV access, 2.3 L N/S has infused on route.
  • You decide to administer blood products

7
  • Red blood cells?
  • Frozen Plasma?
  • Platelets?

8
COST Coagulopathy of Severe Trauma
  • Hypothermia
  • Acidosis
  • Dilution

9
COST Coagulopathy of Severe Trauma
  • Hypothermia
  • Acidosis
  • Dilution
  • Reduces activity of clotting factors by 50 at 34
    C
  • Platelet activation almost eliminated at
  • 30 C

10
COST Coagulopathy of Severe Trauma
  • Hypothermia
  • Acidosis
  • Dilution
  • Xa-Va complex activity reduced
  • pH
  • 7.2 50
  • 7.o 70
  • 6.8 90

11
COST Coagulopathy of Severe Trauma
  • Hypothermia
  • Acidosis
  • Dilution
  • Once thought to be the major cause
  • Late
  • Iatrogenic

12
COST Coagulopathy of Severe Trauma
  • Hypothermia
  • Acidosis
  • Dilution
  • Consumption
  • Fibrinolysis
  • Was thought to be DIC
  • (late)
  • Now recognized as local (early)

13
COST Coagulopathy of Severe Trauma
  • Hypothermia
  • Acidosis
  • Dilution
  • Consumption
  • Fibrinolysis
  • With consumption of thrombin, Thrombin Activated
    Thrombolysis Inhibitor secretion deminished
  • Low flowgtgtTPA secretion

14
COST Coagulopathy of Severe Trauma
  • Hypothermia
  • Acidosis
  • Dilution
  • Consumption
  • Fibrinolysis
  • Severe Trauma victims arrive coagulopathic, even
    if they arent cold or acidotic.

15
Whole Blood Administration
16
(No Transcript)
17
  • COST
  • coagulopathy of
  • severe trauma
  • Success of Whole Blood transfusion

18
  • COST
  • coagulopathy of
  • severe trauma
  • Success of Whole Blood transfusion

More Aggressive Blood Transfusion Ratios 111(?)
19
111 is not the same as Whole Blood
  • If you recombine
  • 1 unit pRBCs
  • 1 unit of FFP
  • 1 unit platelets
  • You get
  • Hb 100
  • Plts 88
  • 65 coagulation factors

20
111 is not the same as Whole Blood
  • If you recombine
  • 1 unit pRBCs
  • 1 unit of FFP
  • 1 unit platelets
  • You get
  • Hb 100 gtgt 90
  • Plts 88 gtgt 61
  • 65 coagulation factors

21
What we are doing
  • Avoid blood transfusion in most trauma patients
  • If you do need to transfuse
  • 11 pRBCs plasma
  • After 5 units, add 1 dose platelets (Buffy Coat)

22
Buffy Coat platelets
  • Ordering platelets has changed
  • 1 adult dose
  • Equivalent to 5 units of plts
  • 4 donors in the plasma of 1 male donor

23
What if our patient is on coumadin?
  • Prothrombin Complex Concentrate
  • Octaplex

24
Octaplex
25
Octaplex
  • Recommended for warfarinized patients with
  • Major bleeding
  • Need for urgent (lt6 hours) surgical procedure.
  • Contraindicated in patients with HIT
  • 20 mL vial give 40 mL over 15 minutes

26
Controversies with Pulmonary Emboli
27
Clinical Case
  • 56 yr healthy male presents to ER with swollen
    right leg, RSCP and SOB
  • Requiring 60 FiO2
  • Stable BP
  • Tachycardic

28
Pulmonary Embolism
  • CT shows bilateral thrombus with saddle
    formation and persistent R leg clot
  • ECHO in the ED reveals hypokinetic,
    dysfunctional RV

29
Common Questions
  • Should I start thrombolytics in the ED?
  • Should I arrange for an IVC filter?

30
Clinical Case
  • Heparin bolus and infusion started
  • Resp/ICU consulted for opinions re thrombolysis
    /- filter insertion
  • ICU decision to transfer to unit for observation
  • Prior to bed coming available - acute
    deterioration
  • SBP drops to 70 despite additional fluids

31
Clinical Case
  • CVC inserted and Levophed started
  • tPA infusion in the ER
  • Gradual resolution over 90 min
  • BP 125/70, HR 95 NSR, O2 Sat 90 2L
  • Pressors weaned
  • Near complete symptom resolution

32
Clinical Case
  • Complications
  • Sigmoid intramural hemorrhage perforation
  • IVC filter insertion
  • Bowel resection complicated by perforation and
    re-bleed
  • Intraabdominal abscess Gram - sepsis
  • 8 wk hospital stay prior to death from MODS

33
Classification of Acute PE
  • Minor PE with normal RV function
  • Major PE with isolated RV dysfunction
  • Major PE with shock

Goldhaber. Intern Med. 1999 Nass. Am J Cardiol.
1999
34
Impact of Clinical Instability at Presentation
Mortality
35
(No Transcript)
36
The Evidence for Thrombolysis
  • Only randomized study comparing lytic to heparin
    alone in patients with shock
  • 8 patients with MPE and Shock
  • Randomized to 1 hr SK infusion vs Heparin
  • All 4 treated with SK lived
  • All 4 treated with Heparin died
  • Trial stopped prematurely for ethical reasons
    (intended n40)

Jerjes-Sanchez et al., J Thromb Thrombolysis, 1995
37
Thrombolytic Administration
  • Similar outcomes
  • Type of thrombolytic
  • Duration of infusion
  • Bolus vs infusion
  • Local vs systemic infusion

UKEP investigators, Eur Heart J, 1987 Levine et
al., Chest, 1990 Goldhaber et al., Chest,
1994 Goldharber et al., Lancet 1993
38
What About Submassive PE?
  • 80 of pts have normal BP at time of dx
  • 27-55 of have ECHO evidence of RV dysfunction

Kasper et al, Heart, 1997 Ribeiro et al, Am Heart
J, 1997
39
Prognostic Importance of RV Dysfunction
40
Stevinson et al, Eur Heart J, 2007
41
Prognostic Importance of RV Dysfunction
  • Prospective study of 205 patients with
    sub-massive PE
  • Identified a subgroup of 127 previously healthy
    patients
  • Primary Outcome at 6 months
  • ECHO, 6 min walk distance (6MWD), and a
    quality-of-life survey
  • 5 pts had inadequate echos, nine lost to
    follow-up, and four died

42
Prognostic Importance of RV Dysfunction
  • Of 109 remaining patients, 45 (41) had
    cardiopulmonary problems at 6 months
  • 18 (17) abnormal RV on ECHO
  • 18 of 109 (17) functional limitation (NYHA gt2)
  • 9 of 109 (8) had both
  • 22 patients (20) indicated at least one index of
    poor quality-of-life
  • health status worse
  • not currently shopping
  • perceived need for oxygen at home.

43
Thrombolysis for Submassive PE?
  • SoRV dysfunction adversely impacts prognosis and
    probably affects long-term QOL in a number of
    patients
  • Does this mean that normotensive pts with
    submassive PE actually benefit from thrombolysis?

44
Do Thrombolytics Improve Outcomes?
  • Retrospective cohort registry study in France
  • 128 stable pts with RV dysfunction
  • 64 lysed pts matched to 64 pts treated with
    heparin alone
  • All short term physiologic benefits lost by 1 wk
  • In-hosp mortality 6.3 lytic vs 0 heparin
  • ICH 4.7 lytic vs 0 heparin
  • No difference in recurrent PE

Hamel et al, Chest, 2001
45
Convincing Evidence?
  • Prospective RCT 256 pts with submassive PE
  • IV Heparin vs tPA
  • Primary end point death or escalation of
    treatment (need for pressors, secondary rescue
    thrombolysis, endotracheal intubation, CPR or
    emergency catheter or surgical embolectomy)
  • At 30d 32 (24.6) vs 9 (11.0) difference
  • Low incidence mortality in both groups (4 vs 2)
  • No difference in complications or recurrence

Konstantidides et al, NEJM, 2002
46
Convincing Evidence?
  • Inconsistent inclusion criteria
  • Large numbers of patients in the control arm who
    received secondary thrombolysis (vague and
    subjective indications)
  • Investigators could break the randomization code
    if clinical deterioration
  • No difference btw groups for pressors, ETT, CPR
    or embolectomy
  • No difference between groups in mortality or PE
    recurrence

Konstantidides et al., NEJM, 2002
47
PEITHO Pulmonary Embolism Thrombolysis Study
  • Comparison Trial Evaluating Efficacy and Safety
    of Single IV Bolus Tenecteplase (TNK) Plus
    Heparin as Compared With Heparin Alone in
    Normotensive Patients (with ECHO and Tn evidence
    of RV dysfunction)
  • Primary Outcome
  • 7d All cause mortality or hemodynamic collapse
  • Estimated enrollment 1000 pts
  • Completion Nov 2010

48
Does This Patient Need an IVC Filter?
  • Indications
  • Contraindications to anticoagulation
  • Major bleeding complications during
    anticoagulation
  • Recurrent embolism despite adequate
    anticoagulation therapy
  • Massive PE when it is believed that additional
    emboli might be lethal

Tapson, NEJM, 2009
49
  • Single best trial assessing effectiveness of IVC
    filters
  • Multicentre RCT at 44 centers in France
  • 2 x 2 trial comparing permanent IVC filter with
    no filter and fixed dose sc heparin vs IV
    unfractionated heparin (200 pts per arm)
  • Primary outcome was occurrence of PE within 12
    days post randomization
  • Secondary outcomes PE, recurrent DVT, death,
    filter complications and major bleeding at 2 years

Decousus et al., NEJM, 1998
50
(No Transcript)
51
(No Transcript)
52
(No Transcript)
53
IVC Filters
  • No patients receiving IVC filters died of acute
    PE, while 80 of early deaths in the non-IVC
    filter group (4/5) was due to PE
  • Filters do not prevent death - they prevent
    death due to pulmonary embolism

Decousus et al, NEJM, 1998 Flinn et al, Arch
Surg, 1996
54
IVC Filters
  • When your best clinical judgment suggests that
    the risk of acute, fatal PE in your patient would
    be significantly reduced by placement of an IVC
    filter, you are probably right
  • Dr. William Flinn

Flinn, J Int Care Med, 2003
55
Conclusions
  • Clinical severity depends on clot burden
    hemodynamic reserve
  • Pts with RV dysfunction do poorly
  • Inc mortality, dec QOL and dec functional scores
  • Thrombolytics
  • Stable PE NO
  • MPE with shock YES
  • Submassive PE (RV dysfunction but no shock) NO
  • Consider an urgent IVC filter in selected pts

56
Applications of Cognitive Psychology
57
Play to your strengths
58
Play to your strengths
  • 234 x 567.4

59
Decision Making
60
(No Transcript)
61
(No Transcript)
62
Questions?
63
Rapid Induction of Therapeutic Hypothermia
64
Case 2
  • 62 yo man, sudden collapse at a mall
  • Bystander CPR x 4 minutes
  • Shocked by firefighters with AED, return of pulse
  • Second arrest on arrival in ED, V.fib
  • 15 minute resuscitation, ROSC

65
  • BP 110/85, HR 111
  • Unresponsive
  • Therapeutic Hypothermia?
  • Where? When? How?

66
Rapid induction of hypothermia
  • Significant efforts being made to shorten cooling
    times

67
Thrombolytics in CA
  • First Case report 1974
  • Bolus SK to 35 yr woman 4 days post-partum
  • Successfully resuscitated and d/c 2/52 later
  • Nearly 100 case reports in literature
  • All retrospective, selection bias
  • All report satisfactory outcomes with relatively
    uncommon adverse effects

68
Thrombolytics in CACase Reports
69
Thrombolytics in Cardiac Arrest
  • Review in Critical Care Medicine 2001
  • Possible benefit
  • Evidence in reducing hemodynamic instability
  • Possible reduction in mortality
  • Low incidence of severe complications
  • Support the empiric use of thrombolytics when
    high suspicion of MPE in cardiac arrest

70
Elevated Troponins Correlate with Increased
Mortality
36

4.8
0
Mortality
La Vecchia, Heart, 2004
71
BNP as a Predictor of Outcome
  • Low median BNP levels may also predict benign
    clinical outcome in PE
  • No correlation between RVSP and BNP
  • Low positive predictive value
  • A cut-off of lt 50 pg/mL identified 95 of
    patients with a benign clinical course

Kucher et al, Circulation, 2003 ten Wolde et al,
Circulation, 2003
72
Catheter Embolectomy in PE
  • Indications
  • Contraindication to thrombolytics
  • Persistent hypotension despite thrombolysis
  • Ongoing/Intermittent cardiac arrest
  • Various devices available
  • Fragmentation (Pigtail, Clot Buster)
  • Rheolytic (Angiojet, Hydrolyser)
  • Aspiration (Meverovitz, Greenfield)

73
Catheter Fragmentation
  • Prospective Interventional Study
  • 10 pts with massive PE
  • Rotatable pigtail fragmentation systemic
    thrombolytics
  • Successful recanalization hemodynamic
    improvement in 70 pts
  • Mortality 20 - No significant complications

Schmitz-Rode et al., Chest 1998
74
Surgical Embolectomy in MPE
  • Several retrospective case reports
  • Contraindication/Failure of thrombolytics
  • Interventional radiology unavailable
  • Most suffered CA before or during surgery
  • Major predictive factor is need for CPR

75
Surgical Embolectomy in MPE
76
Surgical Embolectomy in Submassive PE
  • 29 pts with submassive PE and moderate to severe
    RV dysfunction
  • Surgical technique without aortic crossclamp or
    cardioplegia
  • IVC Filters in all patients
  • 11 30d mortality
  • 26/29 pts survival

Aklog et al, Circulation 2002
Write a Comment
User Comments (0)
About PowerShow.com